Simponi orchestrates only partial "yes" from Scots despite patient access scheme
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium has accepted Merck & Co's anti-TNF-alpha monoclonal antibody Simponi (golimumab) for treating ankylosing spondylitis on the Scottish NHS, but only in doses of 50mg.The consortium has also rejected the use of Bristol-Myers Squibb's Orencia (abatacept) as a second-line treatment rheumatoid arthritis.